The discovery of increased levels of GLAST+ EVs in ALS patients in our study represents a novel avenue for further investigation and offers significant potential for the development of new diagnostic and therapeutic strategies in ALS research. The gene discussed is SLC1A3; the disease is amyotrophic lateral sclerosis.